Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 45

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Oral Adjuvant Curcumin Therapy for Attaining Clinical Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Grammatikopoulou, Maria G., Gkiouras, Konstantinos, Theodoridis, Xenophon, Asteriou, Eleni, Forbes, Alastair, Bogdanos, Dimitrios P.·2018·Nutrients
DOI 10.3390/nu10111737
Open this paper in CoChat — free account

Abstract

Curcumin has demonstrated anti-inflammatory properties and has been investigated as an adjuvant therapy of ulcerative colitis (UC). The scope of this study was to systematically review and meta-analyze the efficacy of oral curcumin administration as an adjuvant therapy of UC. MEDLINE, Cochrane/CENTRAL, ClinicalTrials.gov, WHO-ICT Registry, EMBASE and grey literature were searched for relevant randomized controlled trials (RCTs). The primary outcome was clinical remission (attainment) and the secondary outcome was clinical response (maintenance/failure). Risk of bias was assessed with the Cochrane tool. Odds ratios (OR) were calculated with a Mantel-Haenszel (M-H) random effects model and with a beta-binomial (B-B) random effects model when zero events/cells occurred. Four RCTs met the criteria, but one was removed from the analyses due to inconsistency in protocol details. With the M-H method, treatment with curcumin was significantly superior to placebo in attaining remission in the per-protocol (PP) analysis (OR = 5.83, 95%CI = 1.24–27.43), but not in the intention-to-treat (ITT) analysis (OR = 4.33, 95%CI = 0.78–24.00). However, with the more accurate B-B method, both analyses were insignificant (for PP OR = 4.26, 95%CI = 0.59–31.00, for ITT OR = 3.80, 95%CI = 0.55–26.28). Based on the current available evidence, oral curcumin administration does not seem superior to placebo in attaining remission in patients with UC. Future RCTs should be planned more cautiously with sufficient size and adhere to the ITT analysis in all outcomes.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu10111737

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Research works printed but not linked: 38

  1. Weimers, 2018, The Natural History of IBD: Lessons Learned, Curr. Treat. Opt. Gastroenterol., 16, 101, 10.1007/s11938-018-0173-3 · DOI
  2. Durchschein, 2016, Diet therapy for inflammatory bowel diseases: The established and the new, World J. Gastroenterol., 22, 2179, 10.3748/wjg.v22.i7.2179 · DOI
  3. Limketkai, 2018, Nutritional Interventions in the Patient with Inflammatory Bowel Disease, Gastroenterol. Clin. N. Am., 47, 155, 10.1016/j.gtc.2017.09.007 · DOI
  4. Eustace, 2018, Therapy for Crohn’s Disease: A Review of Recent Developments, Curr. Gastroenterol. Rep., 20, 19, 10.1007/s11894-018-0625-x · DOI
  5. Neurath, 2017, Current and emerging therapeutic targets for IBD, Nat. Rev. Gastroenterol. Hepatol., 14, 269, 10.1038/nrgastro.2016.208 · DOI
  6. Larussa, 2017, Potential role of nutraceutical compounds in inflammatory bowel disease, World J. Gastroenterol., 23, 2483, 10.3748/wjg.v23.i14.2483 · DOI
  7. Alizadeh, 2018, Curcumin nanomicelle improves semen parameters, oxidative stress, inflammatory biomarkers, and reproductive hormones in infertile men: A randomized clinical trial, Phytother. Res., 32, 514, 10.1002/ptr.5998 · DOI
  8. Negi, 1999, Antibacterial Activity of Turmeric Oil: A Byproduct from Curcumin Manufacture, J. Agric. Food Chem., 47, 4297, 10.1021/jf990308d · DOI
  9. Amalraj, 2017, A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study, J. Med. Food, 20, 1022, 10.1089/jmf.2017.3930 · DOI
  10. Asteriou, E., Gkoutzourelas, A., Mavropoulos, A., Katsiari, C., Sakkas, L., and Bogdanos, D. (2018). Curcumin for the Management of Periodontitis and Early ACPA-Positive Rheumatoid Arthritis: Killing Two Birds with One Stone. Nutrients, 10. · DOI
  11. Panahi, 2017, Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial, Complement. Ther. Med., 33, 1, 10.1016/j.ctim.2017.05.006 · DOI
  12. Strahler, 2017, Curcumin supplementation improves vascular endothelial function in healthy middle-aged and older adults by increasing nitric oxide bioavailability and reducing oxidative stress, Aging, 9, 187, 10.18632/aging.101149 · DOI
  13. Garg, 2012, Curcumin for maintenance of remission in ulcerative colitis, Cochrane Database Syst. Rev., 10, CD008424
  14. Ali, 2012, Curcumin and inflammatory bowel disease: Biological mechanisms and clinical implication, Digestion, 85, 249, 10.1159/000336720 · DOI
  15. Hanai, 2006, Curcumin maintenance therapy for ulcerative colitis: Randomized, multicenter, double-blind, placebo-controlled trial, Clin. Gastroenterol. Hepatol., 4, 1502, 10.1016/j.cgh.2006.08.008 · DOI · Paper page
  16. Holt, 2005, Curcumin Therapy in Inflammatory Bowel Disease: A Pilot Study, Dig. Dis. Sci., 50, 2191, 10.1007/s10620-005-3032-8 · DOI
  17. Rachmilewitz, 1989, Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: A randomised trial, BMJ, 298, 82, 10.1136/bmj.298.6666.82 · DOI · Paper page
  18. Walmsley, 1998, A simple clinical colitis activity index, Gut, 43, 29, 10.1136/gut.43.1.29 · DOI · Paper page
  19. Sutherland, 1987, 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis, Gastroenterology, 92, 1894, 10.1016/0016-5085(87)90621-4 · DOI · Paper page
  20. Baron, 1964, Variation between observers in describing mucosal appearances in proctocolitis, Br. Med. J., 1, 89, 10.1136/bmj.1.5375.89 · DOI
  21. Schroeder, 1987, Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis, N. Engl. J. Med., 317, 1625, 10.1056/NEJM198712243172603 · DOI
  22. Sandborn, 2007, A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults with Ulcerative Colitis, Gastroenterology, 132, 763, 10.1053/j.gastro.2006.12.038 · DOI · Paper page
  23. Andrews, 2013, GRADE guidelines: 14. Going from evidence to recommendations: The significance and presentation of recommendations, J. Clin. Epidemiol., 66, 719, 10.1016/j.jclinepi.2012.03.013 · DOI · Paper page
  24. Jadad, 1996, Assessing the quality of reports of randomized clinical trials: Is blinding necessary?, Control. Clin. Trials, 17, 1, 10.1016/0197-2456(95)00134-4 · DOI · Paper page
  25. Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J. Natl. Cancer Inst., 22, 719
  26. (2014). The Nordic Cochrane Centre Review Manager, Cochrane Collaboration.
  27. Sharma, 2017, The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials, J. Clin. Epidemiol., 91, 129, 10.1016/j.jclinepi.2017.07.006 · DOI
  28. Lang, 2015, Curcumin in Combination with Mesalamine Induces Remission in Patients with Mild-to-Moderate Ulcerative Colitis in a Randomized Controlled Trial, Clin. Gastroenterol. Hepatol., 13, 1444.e1, 10.1016/j.cgh.2015.02.019 · DOI · Paper page
  29. Kedia, 2017, Low dose oral curcumin is not effective in induction of remission in mild to moderate ulcerative colitis: Results from a randomized double blind placebo controlled trial, World J. Gastrointest. Pharmacol. Ther., 8, 147, 10.4292/wjgpt.v8.i2.147 · DOI · Paper page
  30. Banerjee, 2017, Novel Bio-Enhanced Curcumin with Mesalamine for Induction of Remission in Mild to Moderate Ulcerative Colitis, Gastroenterology, 152, S587, 10.1016/S0016-5085(17)32111-X · DOI
  31. Satsangi, 2006, The Montreal classification of inflammatory bowel disease: Controversies, consensus, and implications, Gut, 55, 749, 10.1136/gut.2005.082909 · DOI
  32. Travis, 2012, Developing an instrument to assess the endoscopic severity of ulcerative colitis: The Ulcerative Colitis Endoscopic Index of Severity (UCEIS), Gut, 61, 535, 10.1136/gutjnl-2011-300486 · DOI · Paper page
  33. Cumming, G. (2011). Understanding the New Statistics: Effect Sizes, Confidence Intervals, and Meta-Analysis, Routledge.
  34. Holt, 2016, Curcumin for Inflammatory Bowel Disease: A Caution, Clin. Gastroenterol. Hepatol., 14, 168, 10.1016/j.cgh.2015.08.036 · DOI
  35. Tsujimoto, 2017, Association between statistical significance and time to publication among systematic reviews: A study protocol for a meta-epidemiological investigation, BMJ Open, 7, e018856, 10.1136/bmjopen-2017-018856 · DOI
  36. Paschos, P., Katsoula, A., Salanti, G., Giouleme, O., Athanasiadou, E., and Tsapas, A. (2018). Systematic review with network meta-analysis: The impact of medical interventions for moderate-to-severe ulcerative colitis on health-related quality of life. Aliment. Pharmacol. Ther. · DOI
  37. Singla, 2014, Induction with NCB-02 (curcumin) enema for mild-to-moderate distal ulcerative colitis—A randomized, placebo-controlled, pilot study, J. Crohns Colitis, 8, 208, 10.1016/j.crohns.2013.08.006 · DOI
  38. Iqbal, 2018, Use of Curcumin in Achieving Clinical and Endoscopic Remission in Ulcerative Colitis: A Systematic Review and Meta-analysis, Am. J. Med. Sci., 356, 350, 10.1016/j.amjms.2018.06.023 · DOI

Cited by

See all 45

Metadata

Authors
Grammatikopoulou, M. G., Gkiouras, K., Theodoridis, X., Asteriou, E., Forbes, A., & Bogdanos, D. P.
Affiliations
  • Faculty of Medicine, School of Health Sciences, University of Thessaly, Mezourlo, GR41110 Larissa, Greece
  • Laboratory of Clinical Pharmacology, Medical School, Faculty of Health Sciences, Aristotle University of Thessaloniki, University Campus, GR54124 Thessaloniki, Greece
  • Department of Rheumatology and Clinical Immunology, Faculty of Medicine, School of Health Sciences, University of Thessaly, Biopolis, GR41110 Larissa, Greece
  • Norwich Medical School, University of East Anglia, Bob Champion Building, James Watson Road, Norwich NR4 7UQ, UK
ORCID
Venue
Nutrients
Publisher
MDPI AG
Published
2018-11-12
Volume
10
Issue
11
Pages
1737
ISSN
2072-6643
DOI
10.3390/nu10111737
Cited by
45
References
10
Language
en
Licence
creativecommons.org/licenses/by/4.0/ (vor)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.